FAKTOR OPTIONSSCHEIN - GENMAB | Market Closed - Boerse Frankfurt Warrants 15:21:03 05/07/2024 BST | ||
| 1.48 EUR | +1.37% |
|
| Current month | -0.67% | ||
| 1 month | -20.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 05/07/24 | 1.48 | +1.37% |
| 04/07/24 | 1.46 | 0.00% |
| 03/07/24 | 1.46 | +2.82% |
| 02/07/24 | 1.42 | -3.40% |
| 01/07/24 | 1.47 | -1.34% |
Real-time Boerse Frankfurt Warrants
Last update July 05, 2024 at 03:21 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
BNP Paribas
|
| WKN | PH2GEN |
| ISIN | DE000PH2GEN1 |
| Date issued | 16/04/2020 |
| Strike | 1,738 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.3 € |
|---|---|
| Lowest since issue | 1.41 € |
| Spread | 0.01 € |
| Spread % | 0.67% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,755
DKK
Average target price
2,464
DKK
Spread / Average Target
+40.40%
- Stock Market
- Certificates
- Certificat
